TY - JOUR T1 - Association of <em>BIM</em> Deletion Polymorphism and <em>BIM-γ</em> RNA Expression in NSCLC with <em>EGFR</em> Mutation JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 475 LP - 482 VL - 13 IS - 6 AU - KAZUTOSHI ISOBE AU - ATSUSHI KAKIMOTO AU - TETSUO MIKAMI AU - KYOHEI KABURAKI AU - HIROSHI KOBAYASHI AU - TAKAHIRO YOSHIZAWA AU - TAKASHI MAKINO AU - HAJIME OTSUKA AU - GO SANO AU - KEISHI SUGINO AU - SUSUMU SAKAMOTO AU - YUJIRO TAKAI AU - NAOBUMI TOCHIGI AU - AKIRA IYODA AU - SAKAE HOMMA Y1 - 2016/11/01 UR - http://cgp.iiarjournals.org/content/13/6/475.abstract N2 - Aim: This pilot study assessed the association of BIM deletion polymorphism and BIM RNA isoform in patients with EGFR-positive non-small cell lung cancer (NSCLC). Patients and Methods: The study included 33 patients with EGFR-positive NSCLC treated with gefitinib. BIM deletion polymorphism and BIM RNA isoform (EL/L/S/γ) were determined by polymerase chain reaction (PCR). Results: BIM-γ expression was significantly higher in patients with BIM deletion polymorphism than among those without BIM deletion polymorphism inside tumors (p=0.038) and around tumors (p=0.0024). Relative BIM-γ expression was significantly higher in patients with BIM deletion polymorphism than among those without BIM deletion polymorphism (p=0.0017). Patients with BIM-γ had significantly shorter progression-free survival than those without BIM-γ (median: 304 vs. 732 days; p=0.023). Conclusion: Expression of BIM-γ mRNA and BIM deletion polymorphism were strongly associated. BIM-γ overexpression may have a role in apoptosis related to EGFR-tyrosine kinase inhibitor. ER -